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ABSTRACT
Objective: Magnetic resonance imaging (MRI) and
clinical parameters are associated with disease progres-
sion in multiple sclerosis (MS). The aim of this study was
to investigate whether adding MRI parameters to a model
with only clinical parameters could improve these
associations.
Methods: 89 patients (55 women) with recently
diagnosed MS had clinical and MRI evaluation at baseline
(time of diagnosis) and at follow-up after 2.2 years.
Detailed clinical data were available, including disease
type (relapse-onset or progressive-onset) and disability,
as measured by the Expanded Disability Status Scale
(EDSS). MRI parameters included Normalised Brain
Volume (NBV) at baseline, percentage brain volume
change (PBVC/year), T2- and T1-lesion loads and spinal
cord abnormalities. Progression of disability (increase in
EDSS of at least 1 point at follow-up) was the main
outcome measure. For a model containing only clinical
parameters, the added value of MRI parameters was
tested using logistic regression.
Results: PBVC/year and lesion loads at follow-up were
significantly higher in the group with progression. Adding
PBVC/year to a clinical model improved the model,
indicating that MRI parameters added independent
information (p,0.001).
Conclusion: The rate of cerebral atrophy conveys added
information for the progression of disability in patients
with early MS, suggesting that clinical disability is
determined by neurodegenerative changes as depicted by
MRI.
Magnetic resonance imaging (MRI) is a sensitive
method for detecting abnormalities in the brain
and spinal cord that are related to multiple sclerosis
(MS) and is widely used in the management of MS.
The most recent diagnostic criteria for MS
incorporate MRI findings underlining the impor-
tance of imaging studies in making the diagnosis of
MS. One of the main remaining challenges of MRI
research in MS is identifying parameters that are
associated with patient outcome. Unfortunately,
despite its powerful diagnostic properties, associa-
tions between MRI and disease progression are less
straightforward. Correlations between conven-
tional MRI measures such as T2- or T1-lesion load
and disability, as measured by the Expanded
Disability Status Scale (EDSS), are only moderate
to poor in most cross-sectional or longitudinal
studies.1–7 Cerebral atrophy is widely used in
clinical trials and other studies as a marker of
neurodegeneration. Several studies showed that
atrophy is already present at the earliest stages of
disease in patients presenting with an isolated
syndrome or early relapsing remitting (RR) MS.8 9
Results suggest that atrophy is a clinically relevant
marker: in cross-sectional studies, atrophy corre-
lates with disability.3 10–12 In patients with well-
established MS, the (rate of) brain atrophy seems
to be associated with the development of disability
at follow-up.3 13–16 For newly diagnosed patients,
the association between measures of atrophy and
future disability is less clear and reported results
are contradictory.17 18
However, most studies on the associations
between MRI parameters and disability did not
include spinal cord parameters. There are good
reasons to include these parameters. Spinal cord
lesions are more often symptomatic and the EDSS
(the most frequently used disability scale in MS) is
heavily weighted towards motor functioning.
Although up to half of all of spinal cord lesions
may not lead to clinical symptoms, including these
focal and diffuse spinal cord abnormalities
improves the correlation between MRI abnormal-
ities and clinical symptoms.19
As well as MRI parameters, several clinical
parameters such as age at onset, sex and disease
type (relapse or progressive onset) may be asso-
ciated with neurological deterioration.20–23 Probably
the best prognostic models are composed of both
clinical and MRI parameters. However, we are not
aware of other studies that, rather than describing
associations between (longitudinal) MRI and
progression of disability, seek to describe the added
value of MRI compared with use of clinical data
alone. Therefore, the aim of this study was to
investigate whether adding MRI parameters to a
model with only clinical parameters could improve
the associations with clinical disease progression
after a follow-up period of 2 years in a group of
recently diagnosed patients with MS.
METHODS
Patients
From a cohort of 133 patients participating in an
ongoing natural history study of recently diag-
nosed patients with MS, 89 patients (55 women,
34 men) with clinically definite MS were studied.24
These patients had clinical and MRI evaluation at
baseline (at the time of the diagnosis) and at
follow-up after a median of 2.2 years (interquartile
range (IQR): 2.0; 2.4). The remaining 44 patients
could not be included because no pre-contrast T1-
weighted scan was available (17 patients),
patients did not want to undergo an MRI scan at
follow-up (16 patients) or MRI scans were
performed in another hospital (11 patients). No
differences in disease duration, age, EDSS or use of
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disease-modifying therapy (DMT) were observed between
studied group and excluded patients. Detailed clinical data
were available, including age at onset, disease duration at
baseline and disability, as measured by EDSS. Disease type was
classified as relapse-onset or progressive-onset. When patients
suffered from a relapse or used steroids, clinical and MRI
evaluations were delayed by a minimum of 6 weeks. The
institutional medical ethics committee approved the study and
informed consent was obtained from each patient.
MRI
All baseline and follow-up MRI scans were performed on the
same 1.0 Tesla scanner (Magnetom Impact, Siemens, Erlangen,
Germany) according to the same scanning protocol.
Brain
Axial T2- and T1-weighted images were acquired: 25 slices with
a slice thickness of 5 mm, gap 10% (2700/45, 90 and 700/15
[repetition time/echo time]). T1-weighted images were acquired
before and after the administration of gadolinium at baseline.
At follow-up, no gadolinium was used.
Baseline and follow-up T2 hyperintense lesion loads (T2LL,
T2LLfu), T1 hypointense or black holes lesion loads (BHLL,
BHLLfu) and baseline volume of gadolinium-enhancing lesions
(GADLL) were quantified using home-developed semi-auto-
mated software based on a thresholding technique after
identification of lesions by an experienced reader. The ratio
between BHLL and T2LL was calculated for baseline (Black
Holes Ratio (BHR)) and follow-up (BHRfu).
Baseline normalised brain volume (NBV) and percentage
brain volume change (PBVC) were measured on the pre-contrast
T1-weighted images using an automated method called
SIENAX and SIENA, respectively.25 The SIENA procedure began
with brain and skull extraction. Normalisation was achieved by
aligning the two images (ie, each timepoint: baseline and
follow-up) to each other, using the skull as a scaling constraint,
then both brain images are resampled into the space halfway
between the two. After this, the actual brain edge displacement
analysis at subvoxel accuracy was carried out. This method
showed a 0.15% error for SIENA and a brain volume accuracy of
0.5–1% for SIENAX.
Spinal cord
Spinal cord scanning included a cardiac-triggered sagittal dual-
echo conventional spin-echo (CSE) (2,400 to 2,900/20, 80
[repetition time/echo time]) and a sagittal T1-weighted CSE
sequence (500/15 [repetition time/echo time]) with a slice
thickness of 3 mm, interslice gap 10%.
For the whole spinal cord number and size (expressed as their
extension over a number of corresponding vertebral segments)
of spinal cord, abnormalities were scored by two readers in
consensus. Focal lesions (ie, sharply delineated areas of increased
signal intensity [SI]) were considered to be present on CSE scans
if seen on intermediate and T2-weighted MRI. Diffuse
abnormalities were defined as areas with a subtle, poorly
delineated increase of SI, best recognised as areas of SI higher
than spinal cerebrospinal fluid on intermediate-weighted
images.26
Statistical analysis
Patients were dichotomised according to progression of dis-
ability: progression was defined as an increase in EDSS of at
least 1 point (all patients had a baseline EDSS below 6).
Although we did not routinely confirm the progression by
Table 1 Clinical characteristics
Part A: Whole group
Measurement
Whole group No progression Progression
p Value
(n = 89) (n = 53) (n = 36)
median (IQR) median (IQR) median (IQR)
Age (years) 36.5 (29.6; 43.5) 34.2 (29.4; 42.3) 39.3 (33.2; 47.6) ns
Sex (M/F) 34/55 16/37 18/18 ns*
Disease type (relapse-onset/progressive-onset) 74/15 49/4 25/11 0.008*
Use of DMT (yes/no) 21/68 14/39 7/29 ns*
Disease duration (years) 1.6 (0.7; 4.1) 1.5 (0.6; 3.7) 2.6 (0.8; 4.5) ns
EDSS baseline 2.0 (2.0; 3.0) 2.5 (2.0; 3.0) 2.0 (1.6; 3.0) ns
EDSS follow-up 2.5 (2.0; 3.5) 2.0 (1.8; 3.0) 3.5 (3.0; 5.4) ,0.001
Progression rate (change EDSS/year) 0.2 (0.0; 0.5) 0.0 (20.3; 0.3) 0.7 (0.5; 1.0) ,0.001
Part B: Relapse-onset group
Measurement
Whole group No progression Progression
p Value
(n = 74) (n = 49) (n = 25)
median (IQR) median (IQR) median (IQR)
Age (years) 35.5 (29.4; 42.6) 34.2 (29.4; 42.8) 35.8 (27.5; 42.6) ns
Sex (M/F) 23/51 14/35 9/16 ns*
Use of DMT (yes/no) 21/53 14/35 7/18 ns*
Disease duration (years) 1.7 (0.6; 4.4) 1.5 (0.6; 3.8) 3.7 (0.7; 4.8) ns
EDSS baseline 2.0 (1.9; 2.6) 2.5 (2.0; 3.0) 2.0 (1.5; 2.5) 0.021
EDSS follow-up 2.5 (2.0; 3.0) 2.0 (1.5; 3.0) 3.0 (2.5; 4.0) ,0.001
Progression rate (change EDSS/year) 0.2 (0.0; 0.5) 0.0 (20.3; 0.2) 0.7 (0.5; 1.0) ,0.001
Progression, increase in EDSS of at least 1 point ; p value, Mann–Whitney U test was used to test for differences between the progression and the no progression group
IQR, interquartile range (25%; 75%)
*Pearson chi-square
DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; F, female; M, male.
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repeating the clinical evaluation after 3 or 6 months and
therefore do not meet the typically used definition of sustained
progression, we are confident that our patients can be classified
as such using the yearly obtained clinical evaluations. The non-
normal distribution of most data necessitated the use of non-
parametrical tests: median and IQR was used. Spearman rank
correlations for correlations between clinical parameters, MRI
parameters, and between clinical and MRI parameters. The
Mann–Whitney U test was used to test differences in clinical
and MRI parameters between patients with or without
progression. Pearson chi-square test was used to test differences
in categorical parameters (sex, relapse/progressive onset, use of
DMT) between patients with or without progression.
Longitudinal MRI data were annualised to account for
differences in duration of follow-up. To find parameters with
the strongest associations with progression, three models were
Table 2 MRI measurements
Part A: Whole group
Measurement
Whole group No progression Progression
p Value
(n = 89) (n = 53) (n = 36)
median (IQR) median (IQR) median (IQR)
Brain
NBV baseline (ml) 1467 (1422; 1513) 1478 (1433; 1520) 1466 (1400; 1499) ns
T2LL baseline (ml) 3.9 (1.5; 11.9) 3.6 (1.0; 8.5) 5.1 (1.8; 21.3) ns
BHLL baseline (ml) 0.3 (0.0; 0.9) 0.3 (0.0; 0.7) 0.4 (0.1; 1.5) ns
GADLL baseline (ml) 0.0 (0.0; 0.2) 0.0 (0.0; 0.2) 0.0 (0.0; 0.2) ns
T2LL follow-up (ml) 4.7 (1.9; 13.2) 3.3 (1.2; 9.8) 8.3 (2.4; 18.4) 0.011
BHLL follow-up (ml) 0.3 (0.0; 1.0) 0.2 (0.0; 0.4) 0.5 (0.1; 1.5) 0.018
BHR baseline 0.06 (0.00; 0.14) 0.04 (0.00; 0.13) 0.08 (0.02; 0.14) ns
BHR follow-up 0.05 (0.01; 0.11) 0.04 (0.00; 0.11) 0.07 (0.03; 0.18) 0.048
PBVC/year (%/year) 20.9 (21.4; 20.4) 20.8 (21.3; 20.3) 21.3 (21.7; 20.5) 0.011
Change in T2LL/year (ml/year) 0.18 (20.14; 0.69) 0.18 (20.14; 0.40) 0.15 (20.15; 1.27) ns
Percentage change in T2LL/year (%/year) 6.1 (24.7; 14.9) 4.4 (26.1; 12.8) 7.4 (21.8; 24.1) ns
Change in BHLL/year (ml/year) 0.00 (20.06; 0.05) 0.00 (0.00; 0.02) 0.00 (20.06; 0.07) ns
Percentage change in BHLL/year (%/year) 23.3 (219.5; 18.2) 26.0 (223.2; 19.6) 22.4 (213.1; 17.1) ns
Spinal cord
Number of focal lesions baseline 3.0 (1.0; 4.0) 2.0 (1.0; 4.5) 3.0 (1.0; 4.0) ns
Number of segments with focal lesions baseline 2.0 (1.0; 3.4) 2.5 (0.8; 3.1) 2.0 (1.0; 4.3) ns
Number of segments with diffuse lesions baseline 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) ns
Number of focal lesions follow-up 3.0 (1.0; 5.0) 3.0 (1.0; 5.0) 4.0 (2.0; 5.8) ns
Number of segments with focal lesions follow-up 2.5 (1.0; 5.0) 2.5 (1.0; 4.5) 2.5 (2.0; 6.7) ns
Number of segments with diffuse lesions follow-up 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) ns
Part B: Relapse-onset group
Measurement
Whole group No progression Progression
p Value
(n = 74) (n = 49) (n = 25)
median (IQR) median (IQR) median (IQR)
Brain
NBV baseline (ml) 1468 (1430; 1516) 1479 (1440; 1520) 1466 (1405; 1505) ns
T2LL baseline (ml) 3.9 (1.7; 12.3) 3.9 (1.3; 10.0) 3.8 (1.9; 24.2) ns
BHLL baseline (ml) 0.3 (0.0; 0.9) 0.3 (0.0; 0.7) 0.3 (0.0; 1.3) ns
GADLL baseline (ml) 0.0 (0.0; 0.2) 0.0 (0.0; 0.2) 0.0 (0.0; 0.2) ns
T2LL follow-up (ml) 4.7 (2.0; 14.2) 4.1 (1.5; 10.2) 8.5 (2.6; 22.5) 0.034
BHLL follow-up (ml) 0.2 (0.0; 1.1) 0.2 (0.0; 0.6) 0.8 (0.1; 1.6) 0.018
BHR baseline 0.06 (0.00; 0.13) 0.04 (0.00; 0.14) 0.07 (0.02; 0.13) ns
BHR follow-up 0.05 (0.01; 0.12) 0.04 (0.00; 0.11) 0.07 (0.02; 0.18) ns
PBVC/year (%/year) 20.9 (21.5; 20.4) 20.7 (21.3; 20.3) 21.4 (22.0; 20.8) 0.006
Change in T2LL/year (ml/year) 0.18 (20.14; 0.69) 0.18 (20.14; 0.52) 0.57 (20.07; 1.78) ns
Percentage change in T2LL/year (%/year) 6.5 (24.6; 14.9) 4.4 (25.7; 12.8) 8.6 (21.2; 32.4) 0.040
Change in BHLL/year (ml/year) 0.00 (20.06; 0.05) 0.00 (20.08; 0.04) 0.06 (20.06; 0.11) ns
Percentage change in BHLL/year (%/year) 22.5 (219.5; 27.8) 25.8 (224.2; 20.6) 2.5 (210.0; 35.9) ns
Spinal cord
Number of focal lesions baseline 2.5 (1.0; 4.3) 2.0 (1.0; 4.5) 3.0 (1.0; 4.0) ns
Number of segments with focal lesions baseline 2.0 (0.9; 3.1) 2.0 (0.5; 3.3) 2.0 (1.0; 3.4) ns
Number of segments with diffuse lesions baseline 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) ns
Number of focal lesions follow-up 3.0 (1.0; 5.0) 3.0 (1.0; 5.0) 4.0 (2.5; 6.0) ns
Number of segments with focal lesions follow-up 2.5 (1.4; 5.1) 2.5 (0.8; 4.5) 2.5 (2.0; 6.9) ns
Number of segments with diffuse lesions follow-up 0.0 (0.0; 0.0) 0.0 (0.0; 0.0) 0.0 (0.0; 0.1) ns
Progression, increase in EDSS of at least 1 point ; p value, Mann–Whitney U test was used to test for differences between the progression and the no progression group
BHLL, T1 hypointense lesion load (‘‘black holes’’); BHR, ratio BHLL/T2LL; GADLL, T1 gadolinium-enhancing lesion load; IQR, interquartile range (25%; 75%); NBV, normalised brain
volume; PBVC, percentage brain volume change; T2LL, T2 hyperintense lesion load.
Research paper
J Neurol Neurosurg Psychiatry 2008;79:917–923. doi:10.1136/jnnp.2007.124123 919
 group.bmj.com on August 11, 2011 - Published by jnnp.bmj.comDownloaded from 
constructed using forward logistic regression (p value for entry
in model = 0.05). The presence or absence of progression was
the dependent variable in all models. All models were corrected
for use of DMT and follow-up duration. Collinearity was
checked using a correlation-matrix containing all independent
variables. Correlation coefficients above 0.60 were found
between the number of focal spinal cord lesions and the
number of segments with focal spinal cord abnormalities and,
furthermore, between T1 lesion load and BHR at baseline and
between T1 lesion load and T2 lesion load at baseline. We then
avoided the use of number of segments with focal spinal cord
abnormalities and used a combined parameter to avoid
collinearity: sum and difference of T1 and T2 lesion loads at
baseline. Clinical parameters were age, disease duration, type of
disease, sex and EDSS at baseline. MRI parameters were:
conventional lesion loads—sum and difference of T1 and T2
lesion loads at baseline, GADLL, BHR, percentage change in T1
and T2 lesion loads/year; spinal cord—number of focal cord
lesions, number of segments with diffuse cord abnormalities;
brain atrophy—NBV and PBVC/year. First, a model containing
only clinical (clinical model) or MRI (MRI model) parameters
was composed. Second, for a model containing only clinical
parameters, the added value of MRI parameters was tested
(combined model): the parameters found in the clinical model
were entered and, subsequently, the MRI parameters found in
the MRI model were added in a stepwise procedure.
Comparisons between models were made using a likelihood
ratio test and by comparing the area under the receiver operator
characteristics (ROC) curve. For all statistical procedures, SPSS
12.0 for Windows was used.
RESULTS
Descriptive, clinical and MRI parameters at baseline and follow-
up
Patient demographics and clinical data at baseline and follow-up
are presented in table 1. Similar patterns are seen for the whole
group (table 1A) and the relapse-onset group (table 1B).
At baseline, median disease duration was 1.6 years (IQR 0.7;
4.1) (table 1A). Most patients had relapse-onset disease (74;
83.1%); the other 15 (16.9%) patients had progressive-onset
disease. At baseline, minimal disability (EDSS ,3) was present
in most patients (62; 69.7%), 8 (9.0%) patients had EDSS>4. At
follow-up, the number of patients with minimal disability
decreased to 43 (48.3%), EDSS >4 was present in 18 (20.2%)
and >6 in only 8 (9.0%). During follow-up, progression was
noted in 36 (40.4%) patients. Median EDSS increased from 2.0
(IQR 2.0; 3.0) to 2.5 (IQR 2.0; 3.5).
MRI characteristics are presented in table 2. Similar patterns
are seen for the whole group (table 2A) and the relapse-onset
group (table 2B).
As expected for patients this early in the disease, low T2LL
(median 3.9 ml, IQR 1.5; 11.9) and BHLL (median 0.3 ml, IQR
0.0; 0.9) were found at baseline (table 2A). Most patients (56;
62.9%) had no enhancing lesions on the baseline scan. Only 12
patients did not have any spinal cord abnormality. The median
number of focal cord lesions at baseline was 3.0 (IQR 1.0; 4.0)
and unchanged at follow-up (3.0, IQR 1.0; 5.0) (table 2A).
Diffuse spinal cord abnormalities were observed in 13 patients.
T2LL increased significantly during follow-up. The change in
T2LL was 6.1%/year (IQR 24.7; 14.9). The median BHLL
decreased slightly during follow-up (23.3%, IQR 219.5; 18.2).
The rate of atrophy as measured by PBVC/year was 20.9%.
Moderate correlations were found between conventional MRI
parameters at baseline (T2LL (r =20.44, p,0.001), BHLL
(r =20.21, p = 0.021), GADLL (r =20.36, p = 0.001)) and rate
of atrophy (PBVC/year) during follow-up. Strong correlations
were found between baseline and follow-up spinal cord
parameters, the strongest being the number of focal lesions
(r = 0.90, p,0.001), probably reflecting a lack of change: 40
(44.9%) patients did not change. Baseline spinal MRI para-
meters and subsequent changes in number of focal lesions or
segments with focal lesions were not correlated.
We also explored the correlations between clinical and MRI
parameters at baseline. The only significant correlations
between baseline EDSS and baseline MRI parameters were
NBV (r =20.42, p,0.001) and number of segments with focal
(r = 0.25, p = 0.019) or diffuse abnormalities (r = 0.23,
p = 0.034).
Clinical and MRI parameters associated with disease
progression
The group of patients that showed progression of disability was
older and consisted of more male patients compared with the
group with stable disease, although the differences between
groups were not statistically significant (table 1). Patients with
relapse onset (49 out of 53; 92%) more often had stable disease
compared with patients with progressive onset (25 out of 36;
69%) (p = 0.008).
None of the brain and spinal MRI parameters at baseline was
significantly different between groups with or without progres-
sion of disability (table 2A). At follow-up, however, T2LL, BHLL
and BHR were significantly higher in the group with progres-
sion: 8.3 ml compared with 3.3 ml (T2LL, p = 0.011), 0.5 ml
compared with 0.2 ml (BHLL, p = 0.018) and 0.07 compared
with 0.04 (BHR, p = 0.048). At baseline and follow-up, the
number of focal lesions in the spinal cord was higher in the
group with progression, although this difference was not
statistically significant.
Significant correlations were found between EDSS at follow-
up and all brain MRI parameters (except for BHR at baseline) at
any time point. The strongest correlation was found between
NBV at baseline and EDSS at follow-up (r =20.44, p,0.001)
(fig 1). The number of baseline spinal cord lesions (r = 0.23,
p = 0.034) and the number of segments with diffuse abnorm-
alities (r = 0.28, p = 0.009) were correlated weakly with EDSS at
follow-up.
Of the changes in MRI parameters during follow-up, only the
rate of atrophy in PBVC/year was significantly higher in the
group with progression of disability compared with the group
without progression (21.3 (IQR 21.7; 20.5) compared with
20.8 (IQR 21.3; 20.3), p = 0.011) (fig 2a). PBVC/year was also
correlated with annualised change in EDSS (r = 0.23, p = 0.030)
(fig 2b).
Area under the ROC curve for this clinical model was 0.72
(fair).27 Older patients with progressive onset and lower
disability at baseline were at the highest odds of progression.
Only baseline and changes in MRI parameters for both brain
and spinal cord were used in the second model. Rate of atrophy
(PBVC/year) was the only MRI parameter that was selected in
the final MRI model (area under ROC curve, 0.68) (table 4),
indicating that a higher rate of atrophy was associated with
disability progression.
Finally, we tested (in the combined model) whether or not
adding MRI information could improve the model that contains
only clinical parameters. DMT, time between baseline and
follow–up examination, age, type of disease and EDSS at
baseline were entered into the model. A subsequent forward
stepwise procedure selected rate of atrophy in the final
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combined model, indicating that this MRI parameter added
independent information to the clinical model. More formally,
this was confirmed by a likelihood ratio test (change between
models is significant, p,0.001) and increased the area under the
ROC curve when comparing the clinical model only (fair, 0.72)
and the combined model (good, 0.82).27 Progression was higher
in the progressive-onset group (11 patients, 73%) compared
with the relapse-onset group (25 patients, 34%). To exclude the
possibility that the group of patients with a progressive onset
drives the results, the logistic regression procedure was repeated
after exclusion of the progressive-onset group. This confirmed
the results of the whole group analysis.
DISCUSSION
The precise role of MRI in the management and diagnosis of MS
continues to be debated; MRI is reported to have28 or have not29
added value. The present study describes clinical and MRI
parameters that are associated with progression of disability, as
measured by changes in EDSS in 89 patients with a recent
diagnosis of MS. The main finding from logistic regression
models is the observation that adding MRI parameters (rate of
cerebral atrophy) to a model using only clinical parameters
results in stronger models.
The cerebral atrophy rate, as measured by PBVC/year, is the
MRI parameter that is most strongly associated with progres-
sion of disability. Although several MRI parameters are in use as
summary measures of axonal loss and other processes of
neurodegeneration, atrophy is most commonly used.30–32
Measures of brain atrophy are robust and even agreement
between centres is excellent.33 Atrophy is already present at the
earliest stages of the disease and progresses during further
follow-up.34 35 The atrophy rate in our study (0.9%) is in line
with previous studies. Reports on the short-term associations
between (rate of) atrophy and subsequent disability in patients
early in the RR course of the disease are contradictory. Tiberio et
al.36 did not find associations between changes in atrophy
measures and changes in disability in a small and not so
progressive early MS cohort, whereas in another study of 53
early RRMS patients, in line with our results, atrophy was
associated with disease progression.37 Those apparently contra-
Figure 1 Scatterplot EDSS at follow-up versus NBV. Scatterplot
showing EDSS, Expanded Disability Status Scale (EDSS) at follow-up
versus normalised brain volume (NBV) at baseline, r =20.44; p,0.001
(Spearman rank correlation).
Figure 2 (A) Rate of atrophy for the progression and no progression group. Black line in box represents median; lower and upper boundaries represent
the 25 and 75% percentiles, respectively. The whiskers represent minimum and maximum values. (B) Scatterplot annualised change in Expanded
Disability Status Scale (EDSS) versus percentage brain volume change (PBVC)/year. Scatterplot showing annualised change in EDSS versus PBVC/year,
r =20.23; p = 0.030 (Spearman rank correlation). Progression, increase in EDSS of at least 1 point.The first logistic regression model was created
using only clinical parameters. Type of disease, age and EDSS at baseline were selected as the three independent parameters in the final clinical model
(table 3).
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dictory results may be caused by the inability of applied clinical
scales to registrate real changes in disability, differences in group
size (as in small groups changes might exist undetected), lack of
progression of disability and others. However, we excluded the
results to be driven by the progressive-onset patients.
Despite these difficulties, it seems important to pick up
differences in (rate of) progression early in the disease course: it
has been shown that time to reach EDSS 4 (regarded as a critical
threshold) varies widely between patients, whereas beyond this
threshold disease progression is quite uniform.20 Probably, the
availability and effectiveness of defense/repair mechanisms
differ between patients early in the disease but, beyond a
critical point (our study indicates that this may occur when
axonal damage surpasses a certain threshold), they fail in a
predictable fashion.
Compared with T2LL and BHLL, atrophy seems to reflect
neurodegeneration more closely and is more strongly correlated
with disability. Several studies showed atrophy to be more
strongly associated with future disability than any conventional
MRI parameter.38–40 Our study results are along the same lines:
none of the conventional MRI parameters were shown to be
associated with disease progression in the final model. Lack of
correlation between conventional MRI parameters and clinical
changes might be explained by several mechanisms. First, as
expected in a group of newly diagnosed MS patients, changes in
and total amount of T2LL and BHLL are low in this study.
Second, disease progression on the EDSS was limited. Third,
variability in the clinical expression of MS plaques in different
anatomical locations was not taken into account.41 Extending
the duration of follow-up and thereby increasing the variance of
the measures is likely to enhance correlations between MRI
parameters and clinical outcome. This study suggests that
conventional MRI parameters are modestly associated with
future disability; although not included in the logistic models,
T2LL and BHLL at baseline correlate with EDSS at follow-up
and lesion loads at follow-up are significantly higher in the
group with progressive disease. Of interest is the time lag
needed to establish this association, indicating that a certain
amount of time elapses between the development of lesions,
and possible subsequent (damage to axons and) development of
disability. Such a time lag may explain why studies have a much
longer follow-up;2 the number of lesions at baseline was the best
predictor for disability at 14 years.
As our final model with MRI and clinical parameters included
does not explain all the variance in progression of disability, it is
clear that other factors that were not included may also play a
role. We can only speculate on these factors, but it seems logical
to address the changes that go undetected on conventional MRI
but appear to be going on outside MRI-visible lesions in the so-
called normal appearing brain tissue (NABT). MTR, T1
relaxation times and other methods for studying the NABT
showed evidence of disease activity outside of MRI-visible
lesions and seem to correlate with disability.42–44 Finally, the
redundancy of neuronal pathways in the CNS and the role of
cortical adaptation have been depicted using functional
MRI.45 46
Several spinal cord MRI parameters were correlated with
EDSS at follow-up, although none of these made it into the final
model. Apparently, no independent information is to be gained
from conventional spinal cord imaging. This is disappointing as
neglect of spinal cord involvement is one of the possible
explanations for suboptimal clinico-radiological correlations.
Several studies showed correlations between EDSS and spinal
cord atrophy:47–49 probably more (independent) information is to
be gained when adding measures of spinal cord atrophy, a
measure that could not be embedded in our present study.
Another limitation of our study is the relatively short duration
of follow-up and the fact that many patients had to be excluded
due to missing data (although with similar baseline character-
istics as those retained).
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